At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 130 enrolled
Drug / intervention
Genuair® (Almirall S.A.) +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study Evaluating Preference, Satisfaction and Ease of Use of Inhalers in COPD Diagnosed Patients
In Brief
A Phase 3 clinical trial evaluating Genuair® (Almirall S.A.) and HandiHaler® (Boehringer Ingelheim's) for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 130 participants across 4 sites in 2 countries.
Detailed Summary
Preference study: Genuair vs HandiHaler inhalers in COPD patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesGermany, Netherlands
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2011
First PostedJun 2011
Primary CompletionJan 2012
TodayJul 2026
First PostedJun 30, 2011
Enrollment StartJun 1, 2011
Primary CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 15.0 years ago
Interventions
Genuair® (Almirall S.A.)device
Inhaler with only placebo, once daily, 14 days
HandiHaler® (Boehringer Ingelheim's)device
Inhaler with only placebo, once daily, 14 days